Showing posts with label cycling. Show all posts
Showing posts with label cycling. Show all posts

Wednesday, September 25, 2013

Malcolm Gladwell on "The Sports Gene" and "The Secret Race"


In an article a couple of weeks ago in The New Yorker, Malcolm Gladwell [author of, among others, The Tipping Point: How Little Things Can Make a Big Difference (2000), Blink: The Power of Thinking Without Thinking (2005), and Outliers: The Story of Success (2008)], reviews two relatively recent books on sports performance.



In the fist book, The Sports Gene: Inside the Science of Extraordinary Athletic Performance (2013), David Epstein offers a wide-ranging account of how biological and environmental factors can create amazing athletes. In the other book Gladwell looks at, The Secret Race: Inside the Hidden World of the Tour de France (2013 paper edition), former professional cyclist and Lance Armstrong teammate Tyler Hamilton offers an in-depth and brutally honest account of his career in cycling and his use of performance enhancing drugs.


Man and Superman

In athletic competitions, what qualifies as a sporting chance?

by
September 9, 2013
Élite sports is a contest among athletes with an uneven set of genetic endowments and natural advantages. Illustration by Barry Blitt.
Élite sports is a contest among athletes with an uneven set of genetic endowments and natural advantages. Illustration by Barry Blitt.
Toward the end of The Sports Gene (Penguin/Current), David Epstein makes his way to a remote corner of Finland to visit a man named Eero Mäntyranta. Mäntyranta lives in a small house next to a lake, among the pine and spruce trees north of the Arctic Circle. He is in his seventies. There is a statue of him in the nearby village. “Everything about him has a certain width to it,” Epstein writes. “The bulbous nose in the middle of a softly rounded face. His thick fingers, broad jaw, and a barrel chest covered by a red knit sweater with a stern-faced reindeer across the middle. He is a remarkable-looking man.” What’s most remarkable is the color of his face. It is a “shade of cardinal, mottled in places with purple,” and evocative of “the hue of the red paint that comes from this region’s iron-rich soil.”

Mäntyranta carries a rare genetic mutation. His DNA has an anomaly that causes his bone marrow to overproduce red blood cells. That accounts for the color of his skin, and also for his extraordinary career as a competitive cross-country skier. In cross-country skiing, athletes propel themselves over distances of ten and twenty miles—a physical challenge that places intense demands on the ability of their red blood cells to deliver oxygen to their muscles. Mäntyranta, by virtue of his unique physiology, had something like sixty-five per cent more red blood cells than the normal adult male. In the 1960, 1964, and 1968 Winter Olympic Games, he won a total of seven medals—three golds, two silvers, and two bronzes—and in the same period he also won two world-championship victories in the thirty-kilometre race. In the 1964 Olympics, he beat his closest competitor in the fifteen-kilometre race by forty seconds, a margin of victory, Epstein says, “never equaled in that event at the Olympics before or since.”

In “The Sports Gene,” there are countless tales like this, examples of all the ways that the greatest athletes are different from the rest of us. They respond more effectively to training. The shape of their bodies is optimized for certain kinds of athletic activities. They carry genes that put them far ahead of ordinary athletes.

Epstein tells the story of Donald Thomas, who on the seventh high jump of his life cleared 7' 3.25"—practically a world-class height. The next year, after a grand total of eight months of training, Thomas won the world championships. How did he do it? He was blessed, among other things, with unusually long legs and a strikingly long Achilles tendon—ten and a quarter inches in length—which acted as a kind of spring, catapulting him high into the air when he planted his foot for a jump. (Kangaroos have long tendons as well, Epstein tells us, which is what gives them their special hop.)

Why do so many of the world’s best distance runners come from Kenya and Ethiopia? The answer, Epstein explains, begins with weight. A runner needs not just to be skinny but—more specifically—to have skinny calves and ankles, because every extra pound carried on your extremities costs more than a pound carried on your torso. That’s why shaving even a few ounces off a pair of running shoes can have a significant effect. Runners from the Kalenjin tribe, in Kenya—where the majority of the country’s best runners come from—turn out to be skinny in exactly this way. Epstein cites a study comparing Kalenjins with Danes; the Kalenjins were shorter and had longer legs, and their lower legs were nearly a pound lighter. That translates to eight per cent less energy consumed per kilometre. (For evidence of the peculiar Kalenjin lower leg, look up pictures of the great Kenyan miler Asbel Kiprop, a tall and elegant man who runs on what appear to be two ebony-colored pencils.) According to Epstein, there’s an evolutionary explanation for all this: hot and dry environments favor very thin, long-limbed frames, which are easy to cool, just as cold climates favor thick, squat bodies, which are better at conserving heat.

Distance runners also get a big advantage from living at high altitudes, where the body is typically forced to compensate for the lack of oxygen by producing extra red blood cells. Not too high up, mind you. In the Andes, for example, the air is too rarefied for the kind of workouts necessary to be a world-class runner. The optimal range is six to nine thousand feet. The best runners in Ethiopia and Kenya come from the ridges of the Rift Valley, which, Epstein writes, are “plumb in the sweet spot.” When Kenyans compete against Europeans or North Americans, the Kenyans come to the track with an enormous head start.

What we are watching when we watch élite sports, then, is a contest among wildly disparate groups of people, who approach the starting line with an uneven set of genetic endowments and natural advantages. There will be Donald Thomases who barely have to train, and there will be Eero Mäntyrantas, who carry around in their blood, by dumb genetic luck, the ability to finish forty seconds ahead of their competitors. Élite sports supply, as Epstein puts it, a “splendid stage for the fantastic menagerie that is human biological diversity.” The menagerie is what makes sports fascinating. But it has also burdened high-level competition with a contradiction. We want sports to be fair and we take elaborate measures to make sure that no one competitor has an advantage over any other. But how can a fantastic menagerie ever be a contest among equals?


During the First World War, the U.S. Army noticed a puzzling pattern among the young men drafted into military service. Soldiers from some parts of the country had a high incidence of goitre—a lump on their neck caused by the swelling of the thyroid gland. Thousands of recruits could not button the collar of their uniform. The average I.Q. of draftees, we now suspect, also varied according to the same pattern. Soldiers from coastal regions seemed more “normal” than soldiers from other parts of the country.

The culprit turned out to be a lack of iodine. Iodine is an essential micronutrient. Without it, the human brain does not develop normally and the thyroid begins to enlarge. And in certain parts of the United States in those years there wasn’t enough iodine in the local diet. As the economists James Feyrer, Dimitra Politi, and David Weil write, in a recent paper for the National Bureau of Economic Research:
Ocean water is rich in iodine, which is why endemic goiter is not observed in coastal areas. From the ocean, iodine is transferred to the soil by rain. This process, however, only reaches the upper layers of soil, and it can take thousands of years to complete. Heavy rainfall can cause soil erosion, in which case the iodine-rich upper layers of soil are washed away. The last glacial period had the same effect: iodine-rich soil was substituted by iodine-poor soil from crystalline rocks. This explains the prevalence of endemic goiter in regions that were marked by intense glaciation, such as Switzerland and the Great Lakes region.
After the First World War, the U.S. War Department published a report called “Defects Found in Drafted Men,” which detailed how the incidence of goitre varied from state to state, with rates forty to fifty times as high in places like Idaho, Michigan, and Montana as in coastal areas.

The story is not dissimilar from Epstein’s account of Kenyan distance runners, in whom accidents of climate and geography combine to create dramatic differences in abilities. In the early years of the twentieth century, the physiological development of American children was an example of the “fantastic menagerie that is human biological diversity.”

In this case, of course, we didn’t like the fantastic menagerie. In 1924, the Morton Salt Company, at the urging of public-health officials, began adding iodine to its salt, and initiated an advertising campaign touting its benefits. That practice has been applied successfully in many developing countries in the world: iodine supplementation has raised I.Q. scores by as much as thirteen points—an extraordinary increase. The iodized salt in your cupboard is an intervention in the natural order of things. When a student from the iodine-poor mountains of Idaho was called upon to compete against a student from iodine-rich coastal Maine, we thought of it as our moral obligation to redress their natural inequality. The reason debates over élite performance have become so contentious in recent years, however, is that in the world of sport there is little of that clarity. What if those two students were competing in a race? Should we still be able to give the naturally disadvantaged one the equivalent of iodine? We can’t decide.

Epstein tells us that baseball players have, as a group, remarkable eyesight. The ophthalmologist Louis Rosenbaum tested close to four hundred major- and minor-league baseball players over four years and found an average visual acuity of about 20/13; that is, the typical professional baseball player can see at twenty feet what the rest of us can see at thirteen feet. When Rosenbaum looked at the Los Angeles Dodgers, he found that half had 20/10 vision and a small number fell below 20/9, “flirting with the theoretical limit of the human eye,” as Epstein points out. The ability to consistently hit a baseball thrown at speeds approaching a hundred miles an hour, with a baffling array of spins and curves, requires the kind of eyesight commonly found in only a tiny fraction of the general population.

Eyesight can be improved—in some cases dramatically—through laser surgery or implantable lenses. Should a promising young baseball player cursed with normal vision be allowed to get that kind of corrective surgery? In this instance, Major League Baseball says yes. Major League Baseball also permits pitchers to replace the ulnar collateral ligament in the elbow of their throwing arm with a tendon taken from a cadaver or elsewhere in the athlete’s body. Tendon-replacement surgery is similar to laser surgery: it turns the athlete into an improved version of his natural self.

But when it comes to drugs Major League Baseball—like most sports—draws the line. An athlete cannot use a drug to become an improved version of his natural self, even if the drug is used in doses that are not harmful, and is something that—like testosterone—is no more than a copy of a naturally occurring hormone, available by prescription to anyone, virtually anywhere in the world.

Baseball is in the middle of one of its periodic doping scandals, centering on one of the game’s best players, Alex Rodriguez. Rodriguez is among the most disliked players of his generation. He tried to recover from injury and extend his career through illicit means. (He has appealed his recent suspension, which was based on these allegations.) It is hard to think about Rodriguez, however, and not think about Tommy John, who, in 1974, was the first player to trade in his ulnar collateral ligament for an improved version. John used modern medicine to recover from injury and extend his career. He won a hundred and sixty-four games after his transformation, far more than he did before science intervened. He had one of the longest careers in baseball history, retiring at the age of forty-six. His bionic arm enabled him to win at least twenty games a season, the benchmark of pitching excellence. People loved Tommy John. Maybe Alex Rodriguez looks at Tommy John—and at the fact that at least a third of current major-league pitchers have had the same surgery—and is genuinely baffled about why baseball has drawn a bright moral line between the performance-enhancing products of modern endocrinology and those offered by orthopedics.

The other great doping pariah is Lance Armstrong. He apparently removed large quantities of his own blood and then re-infused himself before competition, in order to boost the number of oxygen-carrying red blood cells in his system. Armstrong wanted to be like Eero Mäntyranta. He wanted to match, through his own efforts, what some very lucky people already do naturally and legally. Before we condemn him, though, shouldn’t we have to come up with a good reason that one man is allowed to have lots of red blood cells and another man is not?

“I’ve always said you could have hooked us up to the best lie detectors on the planet and asked us if we were cheating, and we’d have passed,” Lance Armstrong’s former teammate Tyler Hamilton writes in his autobiography, “The Secret Race” (co-written with Daniel Coyle; Bantam). “Not because we were delusional—we knew we were breaking the rules—but because we didn’t think of it as cheating. It felt fair to break the rules.”

“The Secret Race” deserves to be read alongside “The Sports Gene,” because it describes the flip side of the question that Epstein explores. What if you aren’t Eero Mäntyranta?

Hamilton was a skier who came late to cycling, and he paints himself as an underdog. When he first met Armstrong—at the Tour DuPont, in Delaware—he looked around at the other professional riders and became acutely conscious that he didn’t look the part. “You can tell a rider’s fitness by the shape of his ass and the veins in his legs, and these asses were bionic, smaller and more powerful than any I’d ever seen,” he writes. The riders’ “leg veins looked like highway maps. Their arms were toothpicks. . . . They were like racehorses.” Hamilton’s trunk was oversized. His leg veins did not pop. He had a skier’s thighs. His arms were too muscled, and he pedalled with an ungainly “potato-masher stroke.”

When Hamilton joined Armstrong on the U.S. Postal Service racing team, he was forced to relearn the sport, to leave behind, as he puts it, the romantic world “where I used to climb on my bike and simply hope I had a good day.” The makeover began with his weight. When Michele Ferrari, the key Postal Service adviser, first saw Hamilton, he told him he was too fat, and in cycling terms he was. Riding a bicycle quickly is a function of the power you apply to the pedals divided by the weight you are carrying, and it’s easier to reduce the weight than to increase the power. Hamilton says he would come home from a workout, after burning thousands of calories, drink a large bottle of seltzer water, take two or three sleeping pills—and hope to sleep through dinner and, ideally, breakfast the following morning. At dinner with friends, Hamilton would take a large bite, fake a sneeze, spit the food into a napkin, and then run off to the bathroom to dispose of it. He knew that he was getting into shape, he says, when his skin got thin and papery, when it hurt to sit down on a wooden chair because his buttocks had disappeared, and when his jersey sleeve was so loose around his biceps that it flapped in the wind. At the most basic level, cycling was about physical transformation: it was about taking the body that nature had given you and forcibly changing it.

“Lance and Ferrari showed me there were more variables than I’d ever imagined, and they all mattered: wattages, cadence, intervals, zones, joules, lactic acid, and, of course, hematocrit,” Hamilton writes. “Each ride was a math problem: a precisely mapped set of numbers for us to hit. . . . It’s one thing to go ride for six hours. It’s another to ride for six hours following a program of wattages and cadences, especially when those wattages and cadences are set to push you to the ragged edge of your abilities.”

Hematocrit, the last of those variables, was the number they cared about most. It refers to the percentage of the body’s blood that is made up of oxygen-carrying red blood cells. The higher the hematocrit, the more endurance you have. (Mäntyranta had a very high hematocrit.) The paradox of endurance sports is that an athlete can never work as hard as he wants, because if he pushes himself too far his hematocrit will fall. Hamilton had a natural hematocrit of forty-two per cent—which is on the low end of normal. By the third week of the Tour de France, he would be at thirty-six per cent, which meant a six-per-cent decrease in his power—in the force he could apply to his pedals. In a sport where power differentials of a tenth of a per cent can be decisive, this “qualifies as a deal breaker.”

For the members of the Postal Service squad, the solution was to use the hormone EPO and blood transfusions to boost their hematocrits as high as they could without raising suspicion. (Before 2000, there was no test for EPO itself, so riders were not allowed to exceed a hematocrit of fifty per cent.) Then they would add maintenance doses over time, to counteract the deterioration in their hematocrit caused by races and workouts. The procedures were precise and sophisticated. Testosterone capsules were added to the mix to aid recovery. They were referred to as “red eggs.” EPO (a.k.a. erythropoietin), a naturally occurring hormone that increases the production of red blood cells, was Edgar—short for Edgar Allan Poe. During the Tour de France, and other races, bags of each rider’s blood were collected in secret locations at predetermined intervals, then surreptitiously ferried from stage to stage in refrigerated containers for strategic transfusions. The window of vulnerability after taking a drug—the interval during which doping could be detected—was called “glowtime.” Most riders who doped (and in the Armstrong era, it now appears, nearly all the top riders did) would take two thousand units of Edgar subcutaneously every couple of days, which meant they “glowed” for a dangerously long time. Armstrong and his crew practiced microdosing, taking five hundred units of Edgar nightly and injecting the drug directly into the vein, where it was dispersed much more quickly.

“The Secret Race” is full of paragraphs like this:
The trick with getting Edgar in your vein, of course, is that you have to get it in the vein. Miss the vein—inject it in the surrounding tissue—and Edgar stays in your body far longer; you might test positive. Thus, microdosing requires a steady hand and a good sense of feel, and a lot of practice; you have to sense the tip of the needle piercing the wall of the vein, and draw back the plunger to get a little bit of blood so you know you’re in. In this, as in other things, Lance was blessed: he had veins like water mains. Mine were small, which was a recurring headache.
Hamilton was eventually caught and was suspended from professional cycling. He became one of the first in his circle to implicate Lance Armstrong, testifying before federal investigators and appearing on “60 Minutes.” He says that he regrets his years of using performance-enhancing drugs. The lies and duplicity became an unbearable burden. His marriage fell apart. He sank into a depression. His book is supposed to serve as his apology. At that task, it fails. Try as he might—and sometimes he doesn’t seem to be trying very hard—Hamilton cannot explain why a sport that has no problem with the voluntary induction of anorexia as a performance-enhancing measure is so upset about athletes infusing themselves with their own blood.

“Dope is not really a magical boost as much as it is a way to control against declines,” Hamilton writes. Doping meant that cyclists finally could train as hard as they wanted. It was the means by which pudgy underdogs could compete with natural wonders. “People think doping is for lazy people who want to avoid hard work,” Hamilton writes. For many riders, the opposite was true:
EPO granted the ability to suffer more; to push yourself farther and harder than you’d ever imagined, in both training and racing. It rewarded precisely what I was good at: having a great work ethic, pushing myself to the limit and past it. I felt almost giddy: this was a new landscape. I began to see races differently. They weren’t rolls of the genetic dice, or who happened to be on form that day. They didn’t depend on who you were. They depended on what you did—how hard you worked, how attentive and professional you were in your preparation.
This is a long way from the exploits of genial old men living among the pristine pines of northern Finland. It is a vision of sports in which the object of competition is to use science, intelligence, and sheer will to conquer natural difference. Hamilton and Armstrong may simply be athletes who regard this kind of achievement as worthier than the gold medals of a man with the dumb luck to be born with a random genetic mutation.

Thursday, September 19, 2013

Curcumin Prevents Replication of Respiratory Virus; Caffeine Increases Anaerobic Performance in Cycling


Two new studies from PLoS ONE today, each one focusing on favorite substances of mine - curcumin and caffeine.

In the first one, researchers found curcumin (the yellow stuff in turmeric) to be as effective as pharmaceuticals in stopping the replication of respiratory syncytial virus (RSV), a major cause of bronchitis, asthma, and severe lower respiratory tract disease in infants and young children. Not only that, it also inhibits the epithelial responses to RSV, including the release of pro-inflammatory cytokines. Another use for one of my favorite spices.

In the other study, researchers gave caffeine (CAF) to recreationally trained male cyclists (5 mg.kg−1 body mass) and had them ride a 4000 m time trial. Turns out the caffeine increased mean power output and reduced the total time. Interestingly, in the CAF group, the anaerobic contribution during the 2200-, 2400-, and 2600-m intervals was significantly greater. However, the mean anaerobic and aerobic contributions were similar between conditions. There were also no significant differences between CAF and placebo for anaerobic work, aerobic work, or total work. Moreover, there was no difference for integrated electromyography, blood lactate concentration, heart rate, and ratings of perceived exertion between the conditions. So it seems for cyclists, the performance increase from caffeine manifests in the middle of a 4000 m time trial.

Here are the titles, abstracts, citations, and such.

Curcumin Prevents Replication of Respiratory Syncytial Virus and the Epithelial Responses to It in Human Nasal Epithelial Cells
Kazufumi Obata, Takashi Kojima, Tomoyuki Masaki, Tamaki Okabayashi, Shinichi Yokota, Satoshi Hirakawa, Kazuaki Nomura, Akira Takasawa, Masaki Murata, Satoshi Tanaka, Jun Fuchimoto, Nobuhiro Fujii, Hiroyuki Tsutsumi, Tetsuo Himi, Norimasa Sawada 

Abstract


The human nasal epithelium is the first line of defense during respiratory virus infection. Respiratory syncytial virus (RSV) is the major cause of bronchitis, asthma and severe lower respiratory tract disease in infants and young children. We previously reported in human nasal epithelial cells (HNECs), the replication and budding of RSV and the epithelial responses, including release of proinflammatory cytokines and enhancement of the tight junctions, are in part regulated via an NF-κB pathway. In this study, we investigated the effects of the NF-κB in HNECs infected with RSV. Curcumin prevented the replication and budding of RSV and the epithelial responses to it without cytotoxicity. Furthermore, the upregulation of the epithelial barrier function caused by infection with RSV was enhanced by curcumin. Curcumin also has wide pharmacokinetic effects as an inhibitor of NF-κB, eIF-2α dephosphorylation, proteasome and COX2. RSV-infected HNECs were treated with the eIF-2α dephosphorylation blocker salubrinal and the proteasome inhibitor MG132, and inhibitors of COX1 and COX2. Treatment with salubrinal, MG132 and COX2 inhibitor, like curcumin, prevented the replication of RSV and the epithelial responses, and treatment with salubrinal and MG132 enhanced the upregulation of tight junction molecules induced by infection with RSV. These results suggest that curcumin can prevent the replication of RSV and the epithelial responses to it without cytotoxicity and may act as therapy for severe lower respiratory tract disease in infants and young children caused by RSV infection.
Full Citation: 
Obata K, Kojima T, Masaki T, Okabayashi T, Yokota S, et al. (2013, Sep 18). Curcumin Prevents Replication of Respiratory Syncytial Virus and the Epithelial Responses to It in Human Nasal Epithelial Cells. PLoS ONE, 8(9): e70225. doi:10.1371/journal.pone.0070225

* * * * *

Caffeine Alters Anaerobic Distribution and Pacing during a 4000-m Cycling Time Trial
 
Ralmony de Alcantara Santos, Maria Augusta Peduti Dal Molin Kiss, Marcos David Silva-Cavalcante, Carlos Rafaell Correia-Oliveira, Romulo Bertuzzi, David John Bishop, Adriano Eduardo Lima-Silva

Abstract


The purpose of the present study was to investigate the effects of caffeine ingestion on pacing strategy and energy expenditure during a 4000-m cycling time-trial (TT). Eight recreationally-trained male cyclists volunteered and performed a maximal incremental test and a familiarization test on their first and second visits, respectively. On the third and fourth visits, the participants performed a 4000-m cycling TT after ingesting capsules containing either caffeine (5 mg.kg−1 of body weight, CAF) or cellulose (PLA). The tests were applied in a double-blind, randomized, repeated-measures, cross-over design. When compared to PLA, CAF ingestion increased mean power output [219.1±18.6 vs. 232.8±21.4 W; effect size (ES) = 0.60 (95% CI = 0.05 to 1.16), p = 0.034] and reduced the total time [419±13 vs. 409±12 s; ES = −0.71 (95% CI = −0.09 to −1.13), p = 0.026]. Furthermore, anaerobic contribution during the 2200-, 2400-, and 2600-m intervals was significantly greater in CAF than in PLA (p<0.05). However, the mean anaerobic [64.9±20.1 vs. 57.3±17.5 W] and aerobic [167.9±4.3 vs. 161.8±11.2 W] contributions were similar between conditions (p>0.05). Similarly, there were no significant differences between CAF and PLA for anaerobic work (26363±7361 vs. 23888±6795 J), aerobic work (68709±2118 vs. 67739±3912 J), or total work (95245±8593 vs. 91789±7709 J), respectively. There was no difference for integrated electromyography, blood lactate concentration, heart rate, and ratings of perceived exertion between the conditions. These results suggest that caffeine increases the anaerobic contribution in the middle of the time trial, resulting in enhanced overall performance.
Full Citation: 
Santos RdA, Kiss MAPDM, Silva-Cavalcante MD, Correia-Oliveira CR, Bertuzzi R, et al. (2013, Sep 18). Caffeine Alters Anaerobic Distribution and Pacing during a 4000-m Cycling Time Trial. PLoS ONE, 8(9): e75399. doi:10.1371/journal.pone.0075399

Sunday, May 12, 2013

The Science Behind the Bike: History of the Hour Record (Documentary)


For cycling fans, today was a good day. The Giro d'Italia (one of the three great stage races, along with the Tour de France and the Vuelta Espana) just finished its first week (tomorrow is a rest day), and the Amgen Tour of California (one of the two big American stage races, the other being the USA Pro Challenge in Colorado) began in the heat of Southern California.

One of the ultimate benchmarks in cycling is the Hour Record - the longest distance covered on a bike in one hour. This short documentary takes a look at the history of the Hour Record from Eddie Merckx in the 1970s to the present.

The Science Behind the Bike



The Science Behind the Bike is a series of films that investigate how science and technology have transformed the sport of cycling.

We talk to Olympic gold-medalists Chris Boardman and Rebecca Romero, and Paralympian gold-medalist Sarah Storey, take a trip to a wind tunnel, consult with Team GB physiologists and hear from design experts and cycling legends such as Graeme Obree and Francesco Moser.

In this series you will find out about the legendary Hour Record (the record for the longest distance cycled in one hour), learn about technology, discover the forces that have to be overcome to ride fast and understand how the body deals physiologically when riding at Olympic level.


Watch the full documentary now - (playlist - 33 min)

Sunday, January 27, 2013

Bookforum Omnivore - Is Morality Rational?

Here is an interesting collection of links from Bookforum's Omnivore blog on morality, examined from a variety of angles.


Is morality rational?

JAN 25 2013 
9:00AM


Here is a little bit from the title essay, Is Morality Rational by Michael Hauskeller (it's only a two-page rebuttal to his critics):
I have no problem with minimal rationality. In fact, I occasionally use it myself. What I maintain is not that moral arguments cannot, or should not, be rational in that sense, but rather that the premises on which moral arguments rest cannot be, in a strict sense, rationally justified. Certain conclusions may follow logically from certain premises, but those premises are not themselves founded on logic or are self-evidently true in the sense that it would be irrational or clearly unreasonable to contest their validity. And although I accept the need to maintain minimal rationality, I also believe that it is easy (and potentially dangerous) to overestimate the importance of it. In moral philosophy whether a conclusion follows logically from certain premises is less important than whether those premises are really as unobjectionable as they tend to be presented as. More often than not, emphasising the “minimal rationality” of an argument serves to conceal the weakness of its premises. 

Sunday, September 21, 2008

Spaniard Alberto Contador Set to Win Third Grand Tour

[image from Cycling News]

Yes, Lance Armstrong won 7 consecutive Tour de France titles, but he never won either of the other two Grand Tours (the Giro d'Italia or the Vuelta a España). Until this morning, only four riders in history had won all three Grand Tours. Now a fifth man has done so -- 25-year-old Spaniard Alberto Contador.

[What's interesting is that this kid is clearly the best rider in the sport, having won all three Grand Tours within 14 months, and only missing out on cycling's Grand Slam because Astana (his team) was banned from the Tour de France for past drug issues, before he joined the team.

Next year, Lance Armstrong is slated to return to Astana and be the team leader going into the Tour, which to me is selfish and unfair. He should stay home and raise money for cancer research through other means. His return is all ego.]

Here is the story from Cycling News:

Contador set to make history

By Bjorn Haake in Navacerrada

Alberto Contador (Astana) grimaces
Photo ©: AFP
(Click for larger image)

Just one day separates Spaniard Alberto Contador from his third Grand Tour victory in 14 months, but on Saturday's uphill time trial to Navacerrada, the 25-year-old showed uncharacteristic frailty. Trailing teammate and stage winner Levi Leipheimer by 31 seconds at the top of the 17.1km climb, his face twisted in pain, Contador earned his likely Vuelta a España win the hard way.

He now leads the race by 46 seconds over Leipheimer, and is poised to become only the fifth rider in history to win all three Grand Tours. The race concludes Sunday in Madrid.

Despite his young age, Contador showed his experience when put to the test. Because his legs weren't the best, he decided to change his strategy. "I went a bit more steadily," he said, and thereby missed out on the chance to score his third stage victory in this year's race, but ensured he wouldn't be toppled by Leipheimer.

Contador learned his lesson from two experiences. One was the last-minute invite to the Giro d'Italia, which he received while sitting at the beach. Despite the difficult task without proper preparation, he suffered through to take overall win. He also may have remembered his Olympic time trial, where stormed off the start ramp like a man possessed, but later suffered and faded to just outside the medal spots.

The Spaniard admitted there was a lot of pressure on him. "I was considered the favourite number one." But he drew strength from his form. "When I was training in July and August I sensed that I could win the Vuelta."

Of his three Grand Tour victories he has great memories of all of them and it was difficult to pick the importance of one win over another. "It's true that the Tour de France victory impacted me and probably brought me the most joy. After all, it changed my life." But number two and three are not far behind. "In the Giro, I will never forget the tifosi."

Then there is racing at home in the Vuelta a España, which is also something special. "There were so many fans here this year, it was really special." It gave Contador additional pressure to perform well under the watchful eye of his people, but it also had some advantages. "Racing at home is very nice. You feel a little bit more balanced. You are used to everything. It feels like home."

Contador compared the three races to each other. "The Vuelta has steeper climbs compared to the Tour. There was a lot of spectacle this year." As for the Giro it wasn't so much the parcours that stood out for him. "It was really, really cold this year in Italy."

Contador hadn't given much thought of entering the history books. "I am still young, I want to win races, but I am not thinking about creating a legacy."

Equally, he didn't know yet what was next on his wish list. He felt that he had already achieved a lot. "For a rider of my characteristics, I have won the three Grand Tours. For now I will just enjoy that victory." After he won the Tour de France last year, he was facing similar questions. He had just achieved his three goals. He wanted to become a professional. Then he wanted to race the Tour and finally he wanted to win it. After that was achieved, people asked him what was next. "Then came the Giro d'Italia win and now the Vuelta."

Contador doesn't think too much about the future and will just enjoy his latest win. Of course, some celebrations are on order as well. "My teammate will await me at the hotel and we will have a special dinner, not just the usual pasta and fish..."


Monday, September 08, 2008

Sources: Lance Armstrong Coming Back

Velo News broke the news this morning. I posted this at Stumble Upon this morning, but figured it might get wider attention here. This is a HUGE deal for cycling, a much needed shot in the arm for a sport that has been mostly getting black eyes.
Sources: Lance Armstrong coming back

Armstrong at Leadville Race

Lance Armstrong will come out of retirement next year to compete in five road races with the Astana team, according to sources familiar with the developing situation.

Armstrong, who turns 37 this month, will compete in the Amgen Tour of California, Paris-Nice, the Tour de Georgia, the Dauphine-Libere and the Tour de France — and will race for no salary or bonuses, the sources, who asked to remain anonymous, told VeloNews.

Armstrong's manager, Mark Higgins, did not respond to questions. And an Astana spokesman denied the report to The Associated Press.

"He is no part of our team," Astana team press officer Philippe Maertens told The AP in an e-mail. "Team Astana has no plans with him."

However sources close to the story have told VeloNews that an exclusive article on the matter will be published in an upcoming issue of Vanity Fair, expected later this month. Vanity Fair editors did not respond to requests for comment.

Rumors of Armstrong's return swirled at last week’s Eurobike trade show in Germany and this week’s Tour of Missouri.

The rumor speculates that Armstrong will reunite with former team manager Johan Bruyneel at Team Astana — a viable option given Armstrong’s long-lasting relationships not only with the Belgian director but also Trek, Astana’s bike sponsor.

According to sources, the Texan will post all of his internally tested blood work online, in an attempt to establish complete transparency and prove that he is a clean athlete.

The rumor, which has been rampant for nearly a month, gained legs when former Discovery Channel team director Dirk Demol signed with Astana for 2009.

“I am excited to be reunited with Johan Bruyneel," Demol said. "What Johan has been able to do this year with Team Astana is quite special and admirable and I look forward to being a part of his program once again. It will be a new team with some familiar faces, but I know the winning philosophy and structure have remained the same.”

Other rumors are that Armstrong will continue to pursue mountain bike racing, and may try his hand at cyclocross as well.

Should Armstrong return with Astana, it would bolster a squad that arguably boasts the sport’s best stage-racing team.

In Missouri, Columbia rider George Hincapie, a close friend of Armstrong’s and the only man to ride on all seven of the Texan’s Tour winning teams, simply smiled when asked what he knew about the rumor, saying, “I don’t know anything.”

Armstrong re-enrolled himself into the U.S. Anti-Doping Agency’s out-of-competition testing pool prior to August’s Leadville Trail 100 mountain bike race, where he finished second to Dave Wiens, said USA Cycling chief operating officer Sean Petty.

USADA rules state that any athlete who wishes to come out of retirement must enroll in the USADA out-of-competition testing program for at least six months in advance of regaining eligible status.

A return to racing would no doubt bring large crowds to American races, and could perhaps save the Tour de Georgia, which is struggling to land a title sponsor.

Petty said that should Armstrong wish to return to racing, “it would be one of most exciting things to happen to American racing since he won his seventh Tour. Depending on his plan, if that is what he wanted to do, it would be tremendously exciting and would generate a tremendous amount of attention on the sport, and on what he’s doing. People would be very interested to see how he would do in a comeback.”

The last big-name rider to return from retirement was Italian Mario Cipollini, who signed with Rock Racing and competed at this year’s Amgen Tour of California after three years away from the sport. Cipollini failed to win a stage, but took third in a field sprint and said, “This finish means as much to me as any victory.” Following the race Cipollini had a contractual dispute with Rock team owner Michael Ball, and left the team.

Thursday, July 17, 2008

More Drug Busts at the Tour de France

[Riccardo Ricco]

There had been two positive tests for EPO in the early stages of this year's Tour de France, and this after all the scandals of the past two years.
Spanish veteran Manuel Beltran -- a former teammate of seven-time Tour champion Lance Armstrong -- was sent home for testing positive for EPO after the first stage this year. Another Spaniard, Moises Duenas Nevado, was detained by police and expelled from the race on Wednesday after testing positive for EPO -- like Ricco, after the fourth stage.
Now there is a third, Riccardo Ricco, who has won two stages of this year's tour and finished second in the Giro d'Italia back in May. He was currently ninth in the GC standings.

From Cycling News:
Italian rider Riccardo Riccò of Saunier Duval has tested positive for blood booster Erythropoietin (EPO), French sports daily L'Equipe reported on its website on Thursday. According to the paper's Damien Ressiot, one of the climber's urine samples collected by the French Anti-Doping Agency AFLD showed traces of a third generation EPO called CERA (Continuous Erythropoietin Receptor Activator), despite there being no WADA-validated test for the drug.

The team's buses and cars were reportedly stopped by gendarmes and searched, and the police were seen taking bags of items away.

The Saunier Duval team has voluntarily withdrawn itself from the Tour de France, and said it would not compete in any races until further notice. Directeur sportif Joxean Fernandez Matxin said he was as surprised as anybody. "We only found out ten minutes ago. The entire team will stop racing, not only in the Tour de France. We suspend the activities of the team until we understand what has happened."

Riccò, who won two stages in the Tour de France (the sixth and ninth), was ninth on general classification before the news broke on Thursday morning. The Italian's impressive performances have in the past been explained by his naturally high hematocrit level.

The Italian from Spanish team Saunier Duval was part of a targeted group of riders. Since the start of the race in Brest, the AFLD performed numerous anti-doping tests on him, at least four according to L'Equipe.

At the start of stage 12 from Lavelanet to Narbonne, Riccò was taken from his team bus into a team car, which took him to the police station. Cyclingnews' Gregor Brown confirmed that the Italian was taken into police custody for questioning.

Fernandez described the final moments before Riccò was driven off. "He sat in the team bus and was not able to say anything. We didn't want to make a scene with the police. They let us drive him away in the team car. A police officer accompanied him in the car."

While the first two positives in the Tour will likely be upheld with the B sample test (they always test two samples), this one is a little more suspect in that the positive result is for a substance that has not accepted test.
Professor Michel Audran is one of the world's leading experts on blood doping. He is also one of nine independent experts chosen to act as consultants in the formulation of the UCI's biological passport. Daniel Friebe, Procycling features editor spoke to Audran this morning within minutes of L'Equipe's website announcing that Riccardo Riccò has tested positive for an EPO derivative after stage four of the Tour de France, the individual time trial around Cholet.

Daniel Friebe: In the last twenty minutes we've heard that Riccardo Riccò has tested positive for an EPO-like product. The early reports suggest that Riccò used CERA or Micera. a so-called third generation EPO. What's your reaction?

Michel Audran: Wow. I'm stunned. I'm amazed they're saying it's Micera, simply because there's no validated test for that yet. The World Anti-Doping Agency is working on a test, but it certainly doesn't exist yet.

DF: What exactly is CERA, or Micera to give it its commercial name?

MA:It's a delayed-action EPO, which has a different molecular mass from EPO. It's only been commercially available since the start of the year. We can tell when someone's used it but we can't declare them positive. In that respect it's like Dynepo, another EPO-like product. We know that Micera was being used on the Giro, so I'm not surprised that it's also turned up at the Tour. But I would be very surprised if they AFLD had declared Riccò positive for Micera, for the reasons I've just mentioned. Maybe they searched Riccò's room and found the product itself...

Read more of this interview.

Adding fuel to this year's controversies around drugs is that the Tour organizers are using their own doping lab rather than that of of the UCI, the international cycling federation. Michel Audran thinks they are targeting specific riders: "What the AFLD have done very well is target particular riders." This accusation has been made in the past around Lance Armstrong and his variuous teams in the Tour.

As much as it sucks for cycling that this is happening, it also seems to be proof that the organizers are trying to clean up the sport. But as long as there is so much pressure to win, and to perform at the impossibly high levels required to compete in the three week stage races, there will be drugs.

Still, it doesn't sem to be as bad as last year's tour:

The Tour continues to struggle to eradicate doping after last year's scandal-plagued event in which two teams withdrew and race leader Michael Rasmussen was kicked out just days before the end for lying about his whereabouts to avoid pre-Tour testing.

Cofidis dropped out after Cristian Moreni of Italy tested positive for testosterone, and pre-race favorite Alexandre Vinokourov's Kazakh-owned Astana team was kicked out by race organizer ASO after he tested positive for blood doping.
Hopefully, things will get better and more riders will stay clean.